Adnexus Therapeutics
Acquired
Pioneering Adnectin therapeutics based on human fibronectin.
- Headquarters
- Waltham, Massachusetts
- Employees
- 1–10
- Founded
- 2003
- Business Model
- B2B
- Website
- adnexus.com
- Total Funding
- $42.5M
- Last Round
- $15.5M Series CAug 2007
About
Adnexus Therapeutics, founded in 2003 and headquartered in Waltham, Massachusetts, was a biopharmaceutical company that pioneered Adnectin therapeutics — engineered variants of the tenth type III domain of human fibronectin. Adnectins were designed as a new protein scaffold platform to generate highly potent, specific, and stable therapeutic agents with favorable half-life and high-yield E. coli production. The company's lead oncology compound, CT-322, was an Adnectin inhibitor of vascular endothelial growth factor receptor-2 (VEGFR-2) developed as an anti-angiogenic cancer therapy. Adnexus was founded by Flagship Pioneering (then Flagship Ventures) and acquired by Bristol-Myers Squibb in September 2007 for approximately $430 million, making it one of the largest biotech acquisitions of that year.
Sign up to view funding chart
Create a free account to see funding visualizations and detailed round data.
Create Free AccountFunding History
Sign up to view funding details
Create a free account to see full funding history, valuations, and investor participation.
Create Free AccountInvestors
Sign up to view investors
Create a free account to see which investors have funded this company.